Research progress in upper digestive tract microbiota and esophageal cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LI Donghang ,  GENG Qing , ZHANG Lin , JIANG Wenyang

Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, P.R.China;

Corresponding author：

GENG Qing, Email: szgqing@126.com

Keywords：

Upper gastrointestinal microbiota; esophageal cancer; mechanism

DOI：

10.7507/1007-4848.201904001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The incidence and mortality of esophageal cancer are high, with strong invasiveness and poor prognosis. In China, the number of morbidity and death accounts for about half of the world. The cause of the disease has not yet been clarified, and it is known to be related to many factors such as chronic damage to the upper digestive tract caused by poor diet and lifestyle, heredity and environment. With the continuous advancement of molecular biology technology, metagenomics and high-throughput sequencing began to be used as non-culture methods instead of traditional culture methods for micro-ecological analysis, and is becoming a research hotspot. Many studies have shown that the disturbance of upper digestive tract microecology may be one of the causes of esophageal cancer, which affects the occurrence and development of esophageal cancer through complex interactions with the body and various mechanisms. This paper reviews the research progress, which is of great significance to further clarify the value of upper gastrointestinal microecology in the pathogenesis, diagnosis and treatment of esophageal cancer.

Citation： LI Donghang, GENG Qing, ZHANG Lin, JIANG Wenyang. Research progress in upper digestive tract microbiota and esophageal cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(1): 90-96. doi: 10.7507/1007-4848.201904001 Copy

1.	Di Pilato V, Freschi G, Ringressi MN, et al. The esophageal microbiota in health and disease. Ann N Y Acad Sci, 2016, 1381(1): 21-33.
2.	Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010, 464(7285): 59-65.
3.	Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol, 2013, 19(10): 1541-1550.
4.	Noone AM HN, Krapcho M, Miller D, et al. SEER cancer statistics review (CSR) 1975–2015, posted to the SEER web site, https://seer.cancer.gov/csr/1975_2015/.
5.	Yang L, Chaudhary N, Baghdadi J, et al. Microbiome in reflux disorders and esophageal adenocarcinoma. Cancer J, 2014, 20(3): 207-210.
6.	Gagliardi D, Makihara S, Corsi PR, et al. Microbial flora of the normal esophagus. Dis Esophagus, 1998, 11(4): 248-250.
7.	Pei Z, Bini EJ, Yang L, et al. Bacterialbiota in the human distal esophagus. Proc Natl Acad Sci USA, 2004, 101(12): 4250-4255.
8.	May M, Abrams JA. Emerging insights into the esophageal microbiome. Curr Treat Options Gastroenterol, 2018, 16(1): 72-85.
9.	Norder Grusell E, Dahlen G, Ruth M, et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus, 2013, 26(1): 84-90.
10.	Pei Z, Yang L, Peek RM, et al. Bacterial biota in reflux esophag it is and Barrett’s esophagus. World J Gastroenterol, 2005, 11(46): 7277-7283.
11.	李博磊, 程磊, 周学东, 等. 口腔微生物与消化系统疾病关系的研究进展. 华西口腔医学杂志, 2018, 36(3): 331-335.
12.	Baghdadi J, Chaudhary N, Pei Z, et al. Microbiome, innate immunity, and esophageal adenocarcinoma. Clin Lab Med, 2014, 34(4): 721-732.
13.	Hunt RH, Yaghoobi M. The esophageal and gastric microbiome in health and disease. Gastroenterol Clin North Am, 2017, 46(1): 121-41.
14.	Eckburg P B, Bik E M, Bernstein C N, et al. Diversity of the human intestinal microbial flora. Science, 2005, 308(5728): 1635-1638.
15.	Costello EK, Lauber CL, Hamady M, et al. Bacterial community variation in human body habitats across space and time. Science, 2009, 326(5960): 1694-1697.
16.	Liu N, Ando T, Ishiguro K, et al. Characterization of bacterial biota in the distal esophagus of Japanese patients with reflux esophagitis and Barrett’s esophagus. BMC Infect Dis, 2013, 13(130): 1-7.
17.	Yang L, Lu X, Nossa CW, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology, 2009, 137(2): 588-597.
18.	Meng C, Bai C, Brown TD, et al. Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bioinformatics, 2018, 16(1): 33-49.
19.	Hold GL. Gastrointestinal microbiota and colon cancer. Dig Dis, 2016, 34(3): 244-250.
20.	Rajagopala SV, Vashee S, Oldfield LM, et al. The human microbiome and cancer. Cancer Prev Res(Phila), 2017, 10(4): 226-2234.
21.	王生, 黄晓星, 余鹏飞, 等. 肠道菌群失调与结肠癌发生发展之间关系的研究进展. 中国药理学通报, 2014, 30(8): 1045-1049.
22.	Yu G, Gail MH, Shi J, et al. Association between upper digestive tract microbiota and cancer‐predisposing states in the esophagus and stomach. Cancer Epidemiol Biomarkers Prev, 2014, 23(5): 735-741.
23.	Nieminen MT, Salaspuro M. Local acetaldehyde-an essential role in alcohol-related upper gastrointestinal tract carcinogenesis. Cancers (Basel), 2018, 10(1): pii:E11.
24.	Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med, 2013, 187(10): 1067-1075.
25.	Sapkota AR, Berger S, Vogel TM. Human pathogens abundant in the bacterial metagenome of cigarettes. Environ Health Perspect, 2010, 118(3): 351-356.
26.	Gong J, Chu Y, Xu M, et al. Esophageal squamous cell carcinoma cell proliferation induced by exposure to low concentration of cigarette smoke extract is mediated via targeting miR-101-3p/ COX-2 pathway. Oncol Rep, 2016, 35(1): 463-471.
27.	Sato F, Oze I, Kawakita D, et al. Inverse association between toothbrushing and upper aerodigestive tract cancer risk in a Japanese population. Head Neck, 2011, 33(11): 1628-1637.
28.	Peters BA, Wu J, Pei Z, et al. Oral microbiome composition reflects prospective risk for esophageal cancers. Cancer Res, 2017, 77(23): 6777-6787.
29.	Michaud DS, Kelsey KT, Papathanasiou E, et al. Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the health professionals follow-up study. Ann Oncol, 2016, 27(5): 941-947.
30.	Chen X, Winckler B, Lu M, et al. Oral microbiota and risk for esophageal squamous cell carcinoma in a high-risk area of China. PloS One, 2015, 10(12): e0143603.
31.	Narikiyo M, Tanabe C, Yamada Y, et al. Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers. Cancer Sci, 2004, 95(7): 569-574.
32.	Chen X, Yuan Z, Lu M, et al. Poor oral health is associated with an increased risk of esophageal squamous cell carcinoma-a population-based case-control study in China. Int J Cancer, 2017, 140(3): 626-635.
33.	Abnet CC, Kamangar F, Islami F, et al. Tooth loss and lack of regular oral hygiene are associated with higher risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev, 2008, 17(11): 3062-3068.
34.	Guha N, Boffetta P, Wunsch Filho V, et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol, 2007, 166(10): 1159-1173.
35.	Abnet CC, Qiao YL, Mark SD, et al. Prospective study of tooth loss and incident esophageal and gastric cancers in China. Cancer Causes Control, 2001, 12(9): 847-854.
36.	Hiraki A, Matsuo K, Suzuki T, et al. Teeth loss and risk of cancer at 14 common sites in Japanese. Cancer Epidemiol Biomarkers Prev, 2008, 17(5): 1222-1227.
37.	Nasrollahzadeh D, Malekzadeh R, Ploner A, et al. Variations of gastric corpus microbiota are associated with early esophageal squamous cell carcinoma and squamous dysplasia. Sci Rep, 2015, 5(3): 8820.
38.	Kondo T, Terada K. Candida esophagitis. N Engl J Med, 2017, 376(16): 1574.
39.	McColl KE. Helicobacter pylori and oesophageal cancer--not always protective. Gut, 2007, 56(4): 457-459.
40.	Gao S, Li S, Ma Z, et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer, 2016, 11: 3.
41.	Kierzkowska M, Majewska A, Młynarczyk G, et al. Microbiologic spectrum and susceptibility of bacteria isolated from patients with intra-abdominal infection. Med Dosw Mikrobiol, 2016, 68(2): 95-102.
42.	Bartosz M, Anna W, Klaudia Z, et al. The role of Tannerella forsythia and Porphyromonas gingivalis in pathogenesis of esophageal cancer. Infect Agent Cancer, 2019, 14: 3.
43.	Bao K, Belibasakis GN, Thurnheer T, et al. Role of Porphyromonasgingivalis gingipains in multi-species biofilm formation. BMC Microbiol, 2014, 14: 258.
44.	Shang Y, Smith S, Hu X. Role of notch signaling in regulating innate immunity and inflammation in health and disease. Protein Cell, 2016, 7(3): 159-174.
45.	Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res, 2012, 18(8): 2138-2144.
46.	Walker MM, Talley NJ. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract-beyond the era of Helicobacter pylori. Aliment Pharmacol Ther, 2014, 39(8): 767-779.
47.	Neto AG, Whitaker A, Pei Z. Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma. Semin Oncol, 2016, 43(1): 86-96.
48.	Zaidi AH, Kelly LA, Kreft RE, et al. Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma. BMC Cancer, 2016, 16: 52.
49.	Jiang Q, Akashi S, Miyake K, et al. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4(TLR4) prior to nuclear translocation of NF-kappa B. J Immunol, 2000, 165(7): 3541-3544.
50.	Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappab, and up-regulating expression of microRNA-21. Gastroenterology, 2017, 152(4): 851-866.
51.	Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer, 2013, 13(11): 800-812.
52.	Gagnière J, Raisch J. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol, 2016, 22(2): 501-518.
53.	Sheflin AM, Whitney AK, Weir TL. Cancer‐promoting effects of microbial dysbiosis. Curr Oncol Rep, 2014, 16(10): 406.
54.	Pikarsky E, Porat RM, Stein I, et al. NF-kappa B functions as a tumour promoter in inflammation-associated cancer. Nature, 2004, 431(7007): 461-466.
55.	Yamamura K, Baba Y, Nakagawa S, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res, 2016, 22(22): 5574-5581.
56.	Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe, 2013, 14(2): 195-206.
57.	Blackett KL, Siddhi SS, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro‐oesophageal reflux disease,Barrett's and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther, 2013, 37(11): 1084-1092.
58.	Macfarlane S, Furrie E, Macfarlane GT, et al. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. Clin Infect Dis, 2007, 45(1): 29-38.
59.	Kaakoush NO, Castaño-Rodríguez, Man SM, et al. Is Campylobacter to esophageal adenocarcinoma as Helicobacter is to gastric adenocarcinoma? Trends Microbiol, 2015, 23(8): 455-462.
60.	Kaakoush NO, Mitchell HM, Man SM. Role of emerging Campylobacter species in inflammatory bowel diseases. Inflamm Bowel Dis, 2014, 20(11): 2189-2197.
61.	Gall A, Fero J, McCoy C, et al. Bacterial composition of the human upper gastrointestinal tract microbiome is dynamic and associated with genomic instability in a Barrett’s esophagus cohort. PLoS One, 2015, 10(6): 1-24.
62.	Xie SH, Lagergren J. Risk factors foroesophageal cancer. Best Pract Res Clin Gastroenterol, 2018, 36-37: 3-8.
63.	Nimptsch K, Steffen A, Pischon T. Obesity and oesophageal cancer. Recent Results Cancer Res, 2016, 208: 67-80.
64.	Kgomo M, Elnagar AA, Mokoena T, et al. Prevalence of helicobacter pylori infection in patients with squamous cell carcinoma of the oesophagus. A descriptive case series study. J Gastrointest Cancer, 2016, 47(4): 396-398.
65.	Nie S, Chen T, Yang X, et al. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma:a meta analysis. Dis Esophagus, 2014, 27(7): 645-653.
66.	Xie FJ, Zhang YP, Zheng QQ, et al. Helicobacter pylori infection and esophageal cancer risk:an updated meta-analysis. World J Gastroenterol, 2013, 19(36): 6098-6107.
67.	Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol, 2016, 41(4): 88-95.
68.	Whiteman DC, Parmar P, Fahey P, et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology, 2010, 139(1): 73-83.
69.	Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut, 2008, 57(6): 727-733.
70.	Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter, 2008, 13(5): 352-360.
71.	Liu TY, Dang YN, Zhuang Y, et al. The study progress on the relationship between gastrointestinal microecology and gastroesophageal reflux disease, Barrett’s esophagus and esophageal adenocarcinoma. Chin J Digest, 2016, 36(3): 211-213.
72.	Wang F, Xia P, Wu F, et al. Helicobacter pylori VacA disrupts apical membrane-cytoskeletal interactions in gastric parietal cells. J Biol Chem, 2008, 283(39): 26714-26725.
73.	Thrift AP, Pandeya N, Smith KJ, et al. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer, 2012, 130(10): 2407-2416.
74.	Misiewicz JJ. Management of Helicobacter pylori-related disorders. Euro J Gastroenterol Hepatol, 2012, 9(Suppl 1): S17-S20.
75.	田志颖, 杨致邦, 黄微微, 等. 幽门螺杆菌感染对小鼠食道下端菌群的影响. 南方医科大学学报, 2014, 34(9): 1241-1247.
76.	Lesmana M. Helicobacter pylori and gastro-esophageal reflux disease (GERD). Univ Med, 2016, 29(1): 46-55.
77.	Chu YX, Wang WH, Dai Y, et al. Esophageal Helicobacter pylori colonization aggravates esophageal injury caused by reflux. World J Gastroenterol, 2014, 20(42): 15715-15726.
78.	Liu FX, Wang WH, Wang J, et al. Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. Helicobacter, 2011, 16(1): 66-77.
79.	Herrera-Goepfert R, Onate-Ocana LF, Mosqueda-Vargas JL, et al. Methylation of DAPK and THBS1 genes in esophageal gastrictype columnar metaplasia. World J Gastroenterol, 2016, 22(18): 4567-4575.
80.	Kilkkinen A, Rissanen H, Klaukka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer, 2008, 123(9): 2152-2155.
81.	Boursi B, Mamtani R, Haynes K, et al. Recurrent antibiotic exposure may promote cancer formation-Another step in understanding the role of the human microbiota? Eur J Cancer, 2015, 51(17): 2655-2664.
82.	Amir I, Konikoff FM, Oppenheim M, et al. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol, 2014, 16(9): 2905-2914.
83.	Hu Q, Sun TT, Hong J, et al. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus:a systematic review and meta-analysis. PLoS One, 2017, 12: e0169691.
84.	Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: What if the results are true? Cancer Epidemiol, 2018, 54(6): 139-140.
85.	Ajayi TA, Cantrell S, Spann A, et al. Barrett's esophagus and esophageal cancer: Links to microbes and the microbiome. PLoS Pathog, 2018, 14(12): e1007384.

1. Di Pilato V, Freschi G, Ringressi MN, et al. The esophageal microbiota in health and disease. Ann N Y Acad Sci, 2016, 1381(1): 21-33.
2. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010, 464(7285): 59-65.
3. Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol, 2013, 19(10): 1541-1550.
4. Noone AM HN, Krapcho M, Miller D, et al. SEER cancer statistics review (CSR) 1975–2015, posted to the SEER web site, https://seer.cancer.gov/csr/1975_2015/.
5. Yang L, Chaudhary N, Baghdadi J, et al. Microbiome in reflux disorders and esophageal adenocarcinoma. Cancer J, 2014, 20(3): 207-210.
6. Gagliardi D, Makihara S, Corsi PR, et al. Microbial flora of the normal esophagus. Dis Esophagus, 1998, 11(4): 248-250.
7. Pei Z, Bini EJ, Yang L, et al. Bacterialbiota in the human distal esophagus. Proc Natl Acad Sci USA, 2004, 101(12): 4250-4255.
8. May M, Abrams JA. Emerging insights into the esophageal microbiome. Curr Treat Options Gastroenterol, 2018, 16(1): 72-85.
9. Norder Grusell E, Dahlen G, Ruth M, et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus, 2013, 26(1): 84-90.
10. Pei Z, Yang L, Peek RM, et al. Bacterial biota in reflux esophag it is and Barrett’s esophagus. World J Gastroenterol, 2005, 11(46): 7277-7283.
11. 李博磊, 程磊, 周学东, 等. 口腔微生物与消化系统疾病关系的研究进展. 华西口腔医学杂志, 2018, 36(3): 331-335.
12. Baghdadi J, Chaudhary N, Pei Z, et al. Microbiome, innate immunity, and esophageal adenocarcinoma. Clin Lab Med, 2014, 34(4): 721-732.
13. Hunt RH, Yaghoobi M. The esophageal and gastric microbiome in health and disease. Gastroenterol Clin North Am, 2017, 46(1): 121-41.
14. Eckburg P B, Bik E M, Bernstein C N, et al. Diversity of the human intestinal microbial flora. Science, 2005, 308(5728): 1635-1638.
15. Costello EK, Lauber CL, Hamady M, et al. Bacterial community variation in human body habitats across space and time. Science, 2009, 326(5960): 1694-1697.
16. Liu N, Ando T, Ishiguro K, et al. Characterization of bacterial biota in the distal esophagus of Japanese patients with reflux esophagitis and Barrett’s esophagus. BMC Infect Dis, 2013, 13(130): 1-7.
17. Yang L, Lu X, Nossa CW, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology, 2009, 137(2): 588-597.
18. Meng C, Bai C, Brown TD, et al. Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bioinformatics, 2018, 16(1): 33-49.
19. Hold GL. Gastrointestinal microbiota and colon cancer. Dig Dis, 2016, 34(3): 244-250.
20. Rajagopala SV, Vashee S, Oldfield LM, et al. The human microbiome and cancer. Cancer Prev Res(Phila), 2017, 10(4): 226-2234.
21. 王生, 黄晓星, 余鹏飞, 等. 肠道菌群失调与结肠癌发生发展之间关系的研究进展. 中国药理学通报, 2014, 30(8): 1045-1049.
22. Yu G, Gail MH, Shi J, et al. Association between upper digestive tract microbiota and cancer‐predisposing states in the esophagus and stomach. Cancer Epidemiol Biomarkers Prev, 2014, 23(5): 735-741.
23. Nieminen MT, Salaspuro M. Local acetaldehyde-an essential role in alcohol-related upper gastrointestinal tract carcinogenesis. Cancers (Basel), 2018, 10(1): pii:E11.
24. Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med, 2013, 187(10): 1067-1075.
25. Sapkota AR, Berger S, Vogel TM. Human pathogens abundant in the bacterial metagenome of cigarettes. Environ Health Perspect, 2010, 118(3): 351-356.
26. Gong J, Chu Y, Xu M, et al. Esophageal squamous cell carcinoma cell proliferation induced by exposure to low concentration of cigarette smoke extract is mediated via targeting miR-101-3p/ COX-2 pathway. Oncol Rep, 2016, 35(1): 463-471.
27. Sato F, Oze I, Kawakita D, et al. Inverse association between toothbrushing and upper aerodigestive tract cancer risk in a Japanese population. Head Neck, 2011, 33(11): 1628-1637.
28. Peters BA, Wu J, Pei Z, et al. Oral microbiome composition reflects prospective risk for esophageal cancers. Cancer Res, 2017, 77(23): 6777-6787.
29. Michaud DS, Kelsey KT, Papathanasiou E, et al. Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the health professionals follow-up study. Ann Oncol, 2016, 27(5): 941-947.
30. Chen X, Winckler B, Lu M, et al. Oral microbiota and risk for esophageal squamous cell carcinoma in a high-risk area of China. PloS One, 2015, 10(12): e0143603.
31. Narikiyo M, Tanabe C, Yamada Y, et al. Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers. Cancer Sci, 2004, 95(7): 569-574.
32. Chen X, Yuan Z, Lu M, et al. Poor oral health is associated with an increased risk of esophageal squamous cell carcinoma-a population-based case-control study in China. Int J Cancer, 2017, 140(3): 626-635.
33. Abnet CC, Kamangar F, Islami F, et al. Tooth loss and lack of regular oral hygiene are associated with higher risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev, 2008, 17(11): 3062-3068.
34. Guha N, Boffetta P, Wunsch Filho V, et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol, 2007, 166(10): 1159-1173.
35. Abnet CC, Qiao YL, Mark SD, et al. Prospective study of tooth loss and incident esophageal and gastric cancers in China. Cancer Causes Control, 2001, 12(9): 847-854.
36. Hiraki A, Matsuo K, Suzuki T, et al. Teeth loss and risk of cancer at 14 common sites in Japanese. Cancer Epidemiol Biomarkers Prev, 2008, 17(5): 1222-1227.
37. Nasrollahzadeh D, Malekzadeh R, Ploner A, et al. Variations of gastric corpus microbiota are associated with early esophageal squamous cell carcinoma and squamous dysplasia. Sci Rep, 2015, 5(3): 8820.
38. Kondo T, Terada K. Candida esophagitis. N Engl J Med, 2017, 376(16): 1574.
39. McColl KE. Helicobacter pylori and oesophageal cancer--not always protective. Gut, 2007, 56(4): 457-459.
40. Gao S, Li S, Ma Z, et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer, 2016, 11: 3.
41. Kierzkowska M, Majewska A, Młynarczyk G, et al. Microbiologic spectrum and susceptibility of bacteria isolated from patients with intra-abdominal infection. Med Dosw Mikrobiol, 2016, 68(2): 95-102.
42. Bartosz M, Anna W, Klaudia Z, et al. The role of Tannerella forsythia and Porphyromonas gingivalis in pathogenesis of esophageal cancer. Infect Agent Cancer, 2019, 14: 3.
43. Bao K, Belibasakis GN, Thurnheer T, et al. Role of Porphyromonasgingivalis gingipains in multi-species biofilm formation. BMC Microbiol, 2014, 14: 258.
44. Shang Y, Smith S, Hu X. Role of notch signaling in regulating innate immunity and inflammation in health and disease. Protein Cell, 2016, 7(3): 159-174.
45. Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res, 2012, 18(8): 2138-2144.
46. Walker MM, Talley NJ. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract-beyond the era of Helicobacter pylori. Aliment Pharmacol Ther, 2014, 39(8): 767-779.
47. Neto AG, Whitaker A, Pei Z. Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma. Semin Oncol, 2016, 43(1): 86-96.
48. Zaidi AH, Kelly LA, Kreft RE, et al. Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma. BMC Cancer, 2016, 16: 52.
49. Jiang Q, Akashi S, Miyake K, et al. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4(TLR4) prior to nuclear translocation of NF-kappa B. J Immunol, 2000, 165(7): 3541-3544.
50. Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappab, and up-regulating expression of microRNA-21. Gastroenterology, 2017, 152(4): 851-866.
51. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer, 2013, 13(11): 800-812.
52. Gagnière J, Raisch J. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol, 2016, 22(2): 501-518.
53. Sheflin AM, Whitney AK, Weir TL. Cancer‐promoting effects of microbial dysbiosis. Curr Oncol Rep, 2014, 16(10): 406.
54. Pikarsky E, Porat RM, Stein I, et al. NF-kappa B functions as a tumour promoter in inflammation-associated cancer. Nature, 2004, 431(7007): 461-466.
55. Yamamura K, Baba Y, Nakagawa S, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res, 2016, 22(22): 5574-5581.
56. Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe, 2013, 14(2): 195-206.
57. Blackett KL, Siddhi SS, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro‐oesophageal reflux disease,Barrett's and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther, 2013, 37(11): 1084-1092.
58. Macfarlane S, Furrie E, Macfarlane GT, et al. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. Clin Infect Dis, 2007, 45(1): 29-38.
59. Kaakoush NO, Castaño-Rodríguez, Man SM, et al. Is Campylobacter to esophageal adenocarcinoma as Helicobacter is to gastric adenocarcinoma? Trends Microbiol, 2015, 23(8): 455-462.
60. Kaakoush NO, Mitchell HM, Man SM. Role of emerging Campylobacter species in inflammatory bowel diseases. Inflamm Bowel Dis, 2014, 20(11): 2189-2197.
61. Gall A, Fero J, McCoy C, et al. Bacterial composition of the human upper gastrointestinal tract microbiome is dynamic and associated with genomic instability in a Barrett’s esophagus cohort. PLoS One, 2015, 10(6): 1-24.
62. Xie SH, Lagergren J. Risk factors foroesophageal cancer. Best Pract Res Clin Gastroenterol, 2018, 36-37: 3-8.
63. Nimptsch K, Steffen A, Pischon T. Obesity and oesophageal cancer. Recent Results Cancer Res, 2016, 208: 67-80.
64. Kgomo M, Elnagar AA, Mokoena T, et al. Prevalence of helicobacter pylori infection in patients with squamous cell carcinoma of the oesophagus. A descriptive case series study. J Gastrointest Cancer, 2016, 47(4): 396-398.
65. Nie S, Chen T, Yang X, et al. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma:a meta analysis. Dis Esophagus, 2014, 27(7): 645-653.
66. Xie FJ, Zhang YP, Zheng QQ, et al. Helicobacter pylori infection and esophageal cancer risk:an updated meta-analysis. World J Gastroenterol, 2013, 19(36): 6098-6107.
67. Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol, 2016, 41(4): 88-95.
68. Whiteman DC, Parmar P, Fahey P, et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology, 2010, 139(1): 73-83.
69. Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut, 2008, 57(6): 727-733.
70. Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter, 2008, 13(5): 352-360.
71. Liu TY, Dang YN, Zhuang Y, et al. The study progress on the relationship between gastrointestinal microecology and gastroesophageal reflux disease, Barrett’s esophagus and esophageal adenocarcinoma. Chin J Digest, 2016, 36(3): 211-213.
72. Wang F, Xia P, Wu F, et al. Helicobacter pylori VacA disrupts apical membrane-cytoskeletal interactions in gastric parietal cells. J Biol Chem, 2008, 283(39): 26714-26725.
73. Thrift AP, Pandeya N, Smith KJ, et al. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer, 2012, 130(10): 2407-2416.
74. Misiewicz JJ. Management of Helicobacter pylori-related disorders. Euro J Gastroenterol Hepatol, 2012, 9(Suppl 1): S17-S20.
75. 田志颖, 杨致邦, 黄微微, 等. 幽门螺杆菌感染对小鼠食道下端菌群的影响. 南方医科大学学报, 2014, 34(9): 1241-1247.
76. Lesmana M. Helicobacter pylori and gastro-esophageal reflux disease (GERD). Univ Med, 2016, 29(1): 46-55.
77. Chu YX, Wang WH, Dai Y, et al. Esophageal Helicobacter pylori colonization aggravates esophageal injury caused by reflux. World J Gastroenterol, 2014, 20(42): 15715-15726.
78. Liu FX, Wang WH, Wang J, et al. Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. Helicobacter, 2011, 16(1): 66-77.
79. Herrera-Goepfert R, Onate-Ocana LF, Mosqueda-Vargas JL, et al. Methylation of DAPK and THBS1 genes in esophageal gastrictype columnar metaplasia. World J Gastroenterol, 2016, 22(18): 4567-4575.
80. Kilkkinen A, Rissanen H, Klaukka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer, 2008, 123(9): 2152-2155.
81. Boursi B, Mamtani R, Haynes K, et al. Recurrent antibiotic exposure may promote cancer formation-Another step in understanding the role of the human microbiota? Eur J Cancer, 2015, 51(17): 2655-2664.
82. Amir I, Konikoff FM, Oppenheim M, et al. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol, 2014, 16(9): 2905-2914.
83. Hu Q, Sun TT, Hong J, et al. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus:a systematic review and meta-analysis. PLoS One, 2017, 12: e0169691.
84. Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: What if the results are true? Cancer Epidemiol, 2018, 54(6): 139-140.
85. Ajayi TA, Cantrell S, Spann A, et al. Barrett's esophagus and esophageal cancer: Links to microbes and the microbiome. PLoS Pathog, 2018, 14(12): e1007384.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progress in upper digestive tract microbiota and esophageal cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content